CanadaBis Capital Inc - Asset Resilience Ratio
CanadaBis Capital Inc (CANB) has an Asset Resilience Ratio of 2.98% as of January 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does CanadaBis Capital Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how CanadaBis Capital Inc's Asset Resilience Ratio has changed over time. See shareholders equity of CanadaBis Capital Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CanadaBis Capital Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CANB stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$700.00K | 2.98% |
| Total Liquid Assets | CA$700.00K | 2.98% |
Asset Resilience Insights
- Limited Liquidity: CanadaBis Capital Inc maintains only 2.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CanadaBis Capital Inc Industry Peers by Asset Resilience Ratio
Compare CanadaBis Capital Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for CanadaBis Capital Inc (2019–2023)
The table below shows the annual Asset Resilience Ratio data for CanadaBis Capital Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-07-31 | 3.05% | CA$700.00K ≈ $506.37K |
CA$22.96 Million ≈ $16.61 Million |
-4.32pp |
| 2019-07-31 | 7.37% | CA$395.00K ≈ $285.74K |
CA$5.36 Million ≈ $3.88 Million |
-- |
About CanadaBis Capital Inc
CanadaBis Capital Inc. engages in the production and sale of recreational cannabis and cannabis extracts in Canada. It operates through two segments: Cultivation and Extraction. The company cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. It is also involved in the production and wholesale distribution of cannabis extract products th… Read more